Raymond James & Associates Glaukos Corp Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Glaukos Corp stock. As of the latest transaction made, Raymond James & Associates holds 13,966 shares of GKOS stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,966
Previous 13,017 7.29%
Holding current value
$1.26 Million
Previous $1.54 Million 18.12%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$113.62 - $135.39 $107,825 - $128,485
949 Added 7.29%
13,966 $1.82 Million
Q2 2024

Jul 19, 2024
BUY
$89.48 - $118.35 $219,404 - $290,194
2,452 Added 23.21%
13,017 $1.54 Million
Q1 2024

Apr 22, 2024
SELL
$76.4 - $96.33 $21,697 - $27,357
-284 Reduced 2.62%
10,565 $996,000
Q4 2023

Jan 16, 2024
SELL
$59.53 - $85.11 $121,976 - $174,390
-2,049 Reduced 15.89%
10,849 $862,000
Q3 2023

Oct 24, 2023
BUY
$69.23 - $79.09 $142,129 - $162,371
2,053 Added 18.93%
12,898 $970,000
Q2 2023

Jul 25, 2023
SELL
$45.44 - $71.21 $57,118 - $89,510
-1,257 Reduced 10.39%
10,845 $772,000
Q1 2023

Apr 14, 2023
SELL
$43.88 - $52.48 $5,660 - $6,769
-129 Reduced 1.05%
12,102 $606,000
Q4 2022

Feb 08, 2023
SELL
$40.82 - $57.75 $166,341 - $235,331
-4,075 Reduced 24.99%
12,231 $534,000
Q3 2022

Oct 25, 2022
BUY
$46.84 - $58.49 $138,505 - $172,954
2,957 Added 22.15%
16,306 $868,000
Q2 2022

Aug 12, 2022
SELL
$34.86 - $63.77 $101,512 - $185,698
-2,912 Reduced 17.91%
13,349 $606,000
Q1 2022

May 11, 2022
SELL
$44.33 - $57.82 $308,802 - $402,774
-6,966 Reduced 29.99%
16,261 $940,000
Q4 2021

Feb 08, 2022
SELL
$40.27 - $56.99 $89,399 - $126,517
-2,220 Reduced 8.72%
23,227 $1.03 Million
Q3 2021

Nov 02, 2021
BUY
$47.43 - $84.23 $319,251 - $566,952
6,731 Added 35.96%
25,447 $1.23 Million
Q2 2021

Aug 11, 2021
BUY
$73.06 - $97.7 $24,109 - $32,241
330 Added 1.79%
18,716 $1.59 Million
Q1 2021

May 14, 2021
SELL
$70.43 - $97.42 $15,283 - $21,140
-217 Reduced 1.17%
18,386 $1.54 Million
Q4 2020

Feb 12, 2021
BUY
$48.9 - $75.26 $62,347 - $95,956
1,275 Added 7.36%
18,603 $1.4 Million
Q3 2020

Nov 04, 2020
BUY
$37.23 - $50.97 $17,051 - $23,344
458 Added 2.71%
17,328 $858,000
Q2 2020

Jul 28, 2020
SELL
$28.78 - $46.83 $88,872 - $144,611
-3,088 Reduced 15.47%
16,870 $648,000
Q1 2020

Apr 21, 2020
BUY
$25.53 - $70.14 $53,306 - $146,452
2,088 Added 11.68%
19,958 $616,000
Q4 2019

Feb 12, 2020
BUY
$54.18 - $65.64 $107,547 - $130,295
1,985 Added 12.5%
17,870 $973,000
Q3 2019

Nov 07, 2019
SELL
$58.58 - $83.91 $175,740 - $251,730
-3,000 Reduced 15.89%
15,885 $993,000
Q2 2019

Aug 06, 2019
SELL
$63.59 - $78.71 $49,282 - $61,000
-775 Reduced 3.94%
18,885 $1.42 Million
Q1 2019

May 06, 2019
BUY
$50.75 - $80.54 $61,458 - $97,533
1,211 Added 6.56%
19,660 $1.54 Million
Q4 2018

Feb 11, 2019
BUY
$52.18 - $67.93 $168,123 - $218,870
3,222 Added 21.16%
18,449 $1.04 Million
Q3 2018

Nov 14, 2018
SELL
$38.13 - $68.37 $44,307 - $79,445
-1,162 Reduced 7.09%
15,227 $988,000
Q2 2018

Aug 14, 2018
BUY
$27.62 - $44.51 $25,382 - $40,904
919 Added 5.94%
16,389 $666,000
Q1 2018

May 14, 2018
SELL
$26.05 - $34.5 $18,834 - $24,943
-723 Reduced 4.46%
15,470 $477,000
Q4 2017

Feb 14, 2018
SELL
$24.5 - $36.01 $52,405 - $77,025
-2,139 Reduced 11.67%
16,193 $415,000
Q3 2017

Nov 13, 2017
BUY
$31.26 - $42.03 $257,676 - $346,453
8,243 Added 81.7%
18,332 $605,000
Q2 2017

Aug 14, 2017
BUY
N/A
10,089
10,089 $418,000

Others Institutions Holding GKOS

# of Institutions
350
Shares Held
48M
Call Options Held
282K
Put Options Held
401K
View Full List

About GLAUKOS Corp

GKOS Quotes by TradingView
  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $4.3B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email